Silexion Therapeutics Corp
Close on Oct 19, 2026
- Market cap
- $105.17K
- P/E (TTM)
- 0.0
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | Before market open | – | $-5.17 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 18, 2026 | Before market open | – | $0.85 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | $-2.88 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 18, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | – | – |
Press releases
Announcements Silexion Therapeutics filed with the SEC
Announces First Patient Successfully Dosed in
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Reports Positive Preclinical Findings for SIL204,
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
AS OF DECEMBER 31, 2025
Other events · EX-99.1 to Form 8-K
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Other events · EX-99.2 to Form 8-K
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Sile ncing Oncogenes at the Level of Gene Expression August 2026 Nasdaq: SLXN
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports New Positive Preclinical Findings Demonstrating Multi-
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally
Regulation FD disclosure · EX-99.1 to Form 8-K
We, Conyers Trust Company (Cayman) Limited, Registered Office of Silexion Therapeutics Corp (the “ Company ”) DO HEREBY CERTIFY that the following is a true extract of the ordinary resolution passed at the
Charter or bylaw amendment · Other events · EX-99 to Form 8-K
Notice shall have the same meanings as defined in the Warrant Agreement.
Charter or bylaw amendment · Other events · EX-99#2 to Form 8-K
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
Other events · EX-99.1 to Form 8-K
Silexion Therapeutics Reports First Quarter 2026 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3
Regulation FD disclosure · EX-99.1 to Form 8-K
Silencing Oncogenes at the Level of Gene Expression Nasdaq: SLXN Company
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Receives Positive Feedback from German Health Authority on
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business
Results of operations · EX-99.1 to Form 8-K
Silexion Therapeutics Announces Positive New Human Cell Line Data
Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA BALANCE SHEET
Unregistered share sale · Other events · EX-99.1 to Form 8-K
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Announces Selection of Contract Research
Regulation FD disclosure · EX-99.1 to Form 8-K
Silencing Oncogenes at the Level of Gene Expression Nasdaq: SLXN Corporate
Regulation FD disclosure · EX-99.1 to Form 8-K
Net of 898 treasury shares held by the Chinese Subsidiary as of December 31, 2023
Other events · EX-99.1 to Form 8-K
Silexion Therapeutics Reports Second Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Silexion Therapeutics Announces New Preclinical Data Showing Up to 97%
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Announces 1-for-15 Reverse Share Split
Other events · EX-99.1 to Form 8-K
Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Completes Key Preclinical Studies Exploring
Regulation FD disclosure · EX-99.1 to Form 8-K
Silexion Therapeutics Reports First Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader
Regulation FD disclosure · EX-99.1 to Form 8-K
Silencing Oncogenes at the Level of Gene Expression Nasdaq: SLXN Corporate
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Silexion Therapeutics Reports Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K